(Q34107268)

31 July 2017

title

Determining the optimal dose of haloperidol in first-episode psychosis (English)

1 reference

31 July 2017

1 reference

1 reference

P Oosthuizen

1

1 reference

31 July 2017

R A Emsley

series ordinal

2

1 reference

31 July 2017

J Turner

series ordinal

3

1 reference

31 July 2017

N Keyter

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Journal of Psychopharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

15

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

251-255

1 reference

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Treatment of schizophrenia in low-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

A prospective, multicenter study of patients' refusal of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

The concept of recovery and secondary prevention in psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Which atypical antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Optimal haloperidol dosage in first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500403

10.1177/026988110101500403

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference